---
title: Paracetamol Route in Palliative Care Patients (PARASCIVPALLIA)
nct_id: NCT03944044
overall_status: UNKNOWN
phase: NA
sponsor: University Hospital, Caen
study_type: INTERVENTIONAL
primary_condition: Palliative Care
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03944044.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03944044"
ct_last_update_post_date: 2022-05-02
last_seen_at: "2026-05-12T07:22:46.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Paracetamol Route in Palliative Care Patients (PARASCIVPALLIA)

**Official Title:** Paracetamol Route in Palliative Care Patients : Intravenous Versus Subcutaneous Route Pharmacokinetics, Study Protocol for a Randomized Equivalence Pilot Trial

**NCT ID:** [NCT03944044](https://clinicaltrials.gov/study/NCT03944044)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** University Hospital, Caen
- **Conditions:** Palliative Care
- **Start Date:** 2019-07-15
- **Completion Date:** 2024-03-01
- **CT.gov Last Update:** 2022-05-02

## Brief Summary

Background: Among palliative-care patients, subcutaneous route is often an alternative to intravenous route yet pharmacological and clinical data are lacking. Many French palliative crew are now using empirically paracetamol by subcutaneous route also there is no data to support this practice. The aim of the present study is to compare pharmacokinetics parameters between intravenous and subcutaneous route for palliative-care patients.

Methods/design: A randomized, open, crossover, bicenter study in two palliative care centers. The aim is to demonstrate the pharmacokinetic equivalence between the two routes of administration. Data analysis will be performed by Wilcoxn's signed Rank Test with an alpha risk of 5 percent. All adverse events will be reported for a safety analysis.

Discussion: This trial may permit, if a pharmacokinetic equivalence is established, to build randomized controlled trials to then assess the efficacy and tolerability of subcutaneous paracetamol administration.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients ≥ 18 years old, hospitalized
* Patients in a palliative care situation
* Patients having an intravenous device with the presence of a venous reflux (be implantable venous site, picc-line, central track)
* Patients having a spontaneous pain, not related to care, with a numeric pain rate scale (NPRS) \> 3/10 or have a systematic prescription of paracetamol in the usual treatment
* Patients able to do an auto-evaluation of their pain by NPRS
* No contraindications of paracetamol
* No contraindications of alternative antalgic (low opioids, strong opioids, Non-steroidal anti-inflammatory)
* Possibility to not take paracetamol in the previous 24 hours before inclusion
* Patients with a blood test dating back less than 7 days, with no severe renal or hepatic failure
* Patients related with a French social security regime
* Patients accept to participate in the study, with written consent.

Exclusion Criteria:

* Patients under legal protection
* Patients who participate in another study less than 30 days before
* Patients weighing less than 50 kg
* Patients having a contraindication to subcutaneous route
* Pregnant or breastfeeding woman
* Patients who having a paracetamol administration less than 24 hours before the beginning of the inclusion
* Patients who having a low opioid less than 2 hours before or a strong opioid less than one hour before the beginning of administration of paracetamol
* Patients having a fever
* No possibility of communication
```

## Arms

- **Subcutaneous route first** (OTHER) — The first route of administration is designated by randomization. In the subcutaneous group, patients received intravenous route in a second time.
- **Intravenous route first** (OTHER) — The first route of administration is designated by randomization. In the intravenous group, patients received subcutaneous route in a second time.

## Interventions

- **Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol** (OTHER) — Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.

## Primary Outcomes

- **paracetamolemia dosage after intravenous route** _(time frame: At injection time)_ — measurement of paracetamol blood concentration after intravenous route
- **paracetamolemia dosage after intravenous route** _(time frame: 15 minutes after injection)_ — measurement of paracetamol blood concentration after intravenous route
- **paracetamolemia dosage after intravenous route** _(time frame: 60 minutes after injection)_ — measurement of paracetamol blood concentration after intravenous route
- **paracetamolemia dosage after intravenous route** _(time frame: 90 minutes after injection)_ — measurement of paracetamol blood concentration after intravenous route
- **paracetamolemia dosage after intravenous route** _(time frame: 120 minutes after injection)_ — measurement of paracetamol blood concentration after intravenous route
- **paracetamolemia dosage after intravenous route** _(time frame: 240 minutes after injection)_ — measurement of paracetamol blood concentration after intravenous route
- **paracetamolemia dosage after intravenous route** _(time frame: 360 minutes after injection)_ — measurement of paracetamol blood concentration after intravenous route
- **paracetamolemia dosage after intravenous route** _(time frame: 480 minutes after injection)_ — measurement of paracetamol blood concentration after intravenous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: at injection time)_ — measurement of paracetamol blood concentration after subcutaneous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: 15 minutes after injection)_ — measurement of paracetamol blood concentration after subcutaneous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: 30 minutes after injection)_ — measurement of paracetamol blood concentration after subcutaneous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: 45 minutes after injection)_ — measurement of paracetamol blood concentration after subcutaneous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: 60 minutes after injection)_ — measurement of paracetamol blood concentration after subcutaneous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: 90 minutes after injection)_ — measurement of paracetamol blood concentration after subcutaneous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: 120 minutes after injection)_ — measurement of paracetamol blood concentration after subcutaneous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: 240 minutes after injection)_ — measurement of paracetamol blood concentration after subcutaneous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: 360 minutes after injection)_ — measurement of paracetamol blood concentration after subcutaneous route
- **paracetamolemia dosage after subcutaneous route** _(time frame: 480 minutes after injection)_ — measurement of paracetamol blood concentration after subcutaneous route

## Secondary Outcomes

- **pain scale** _(time frame: at injection time)_
- **pain scale** _(time frame: 15 minutes after injection time)_
- **pain scale** _(time frame: 60 minutes after injection time)_
- **pain scale** _(time frame: 90 minutes after injection time)_
- **pain scale** _(time frame: 120 minutes after injection time)_
- **pain scale** _(time frame: 240 minutes after injection time)_
- **pain scale** _(time frame: 360 minutes after injection time)_
- **pain scale** _(time frame: 480 minutes after injection time)_

## Locations (1)

- CHU, Caen, France — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chu|caen||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03944044.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03944044*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*